Accéder au contenu
Merck

Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors.

ACS chemical biology (2010-03-02)
Ching-Wen Ho, Shinde D Popat, Ta-Wei Liu, Keng-Chang Tsai, Meng-Jung Ho, Wei-Hung Chen, An-Suei Yang, Chun-Hung Lin
RÉSUMÉ

Human N-acetyl-beta-hexosaminidase (Hex) isozymes are considered to be important targets for drug discovery. They are directly linked to osteoarthritis because Hex is the predominant glycosidase released by chondrocytes to degrade glycosaminoglycan. Hex is also associated with lysosomal storage disorders. We report the discovery of GlcNAc-type iminocyclitiols as potent and selective Hex inhibitors, likely contributed by the gain of extra electrostatic and hydrophobic interactions. The most potent inhibitor had a K(i) of 0.69 nM against human Hex B and was 2.5 x 10(5) times more selective for Hex B than for a similar human enzyme O-GlcNAcase. These glycosidase inhibitors were shown to modulate intracellular levels of glycolipids, including ganglioside-GM2 and asialoganglioside-GM2.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
PUGNAc, ≥95% (HPLC)